? IL-38促進前列腺癌的發展

2024年5月，上海交通大學醫學院附屬銅仁醫院病理科，上海交通大學醫學院附屬銅仁醫院病理科（1 Department of Pathology, Tongji Hospital, Tongji University, Shanghai, China, 2Department of Pathology, Tongren Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China）Shisan Bao2 and Kun Tao1,2研究團隊，在《Frontiers in Immunology》上發表論文：

“IL-38 promotes the development of prostate cancer”

“IL-38促進前列腺癌的發展”

Abstrac：

Introduction: Prostate Cancer (PCa) remains a significant concern in malecancer-related mortality. Tumour development is intricately regulated by the

complex interactions between tumour cells and their microenvironment, makingit essential to determine which is/are key factor(s) that influence the progressionof PCa within the tumour microenvironment.

Materials and methods: The current study utilised histopathology andimmunohistochemistry to determine the expression of IL-38 in PCa and

analysed the correlation between the expression level of IL-38 within PCa and clinical pathological characteristics.

Results: There was a significant increase in IL-38 expression in PCa tissuescompared to adjacent non-PCa tissues (P < 0.0001). In addition, IL-38 expression

was significantly higher in tumour cells with a high proliferation index compared to those with a low value-added index. ROC curve analysis demonstrated that IL-38 has high specificity and sensitivity for the diagnosis of PCa (AUC=0.76).

Moreover, we Probed the cellular source of IL-38 in prostate cancer tissue by immunofluorescence double staining. Additionally, within PCa, the expression of IL-38 was inversely correlated with the expression levels of CD8 and PD-1.

Survival analysis revealed a significantly lower overall survival rate for PCa patients with high IL-38 expression (P=0.0069), and when IL-38 was co-expressed with CD8, the survival rate of the IL-38high/CD8low group was decreased significantly.

Multivariate analysis indicated that the expression level of IL-38 and TNM staging were independent predictors of survival in PCa patients.

Conclusion: These findings suggest that IL-38 plays a crucial role in the development of PCa, and the exploration of the correlation between IL-38 and

various immune factors in the tumour microenvironment further reveals its mechanism of action, making it a potential target for immunotherapy in PCa.

摘要：

簡介:前列腺癌(PCa)仍然是男性癌癥相關死亡率的一個重要問題。腫瘤的發展受到腫瘤細胞與其微環境之間復雜的相互作用的復雜調節，因此確定哪些是影響腫瘤微環境中PCa進展的關鍵因素至關重要。

材料與方法:本研究采用組織病理學和免疫組織化學方法檢測前列腺癌組織中IL-38的表達，分析前列腺癌組織中IL-38表達水平與臨床病理特征的相關性。

結果:前列腺癌組織中IL-38的表達明顯高于癌旁非前列腺癌組織(P < 0.0001)。此外，IL-38在增殖指數高的腫瘤細胞中的表達明顯高于增值指數低的腫瘤細胞。ROC曲線分析顯示IL-38診斷PCa具有較高的特異性和敏感性(AUC=0.76)。此外，科研人員利用免疫熒光雙染色法探索前列腺癌組織中IL-38的細胞來源。此外，在PCa內，IL-38的表達與CD8和PD-1的表達水平呈負相關。生存分析顯示，IL-38高表達組的總生存率顯著降低(P=0.0069)， IL-38與CD8共表達組的生存率顯著降低。多因素分析表明，IL-38表達水平和TNM分期是前列腺癌患者生存的獨立預測因子。

結論:這些發現提示IL-38在前列腺癌的發生發展中起著至關重要的作用，探索IL-38與腫瘤微環境中各種免疫因子的相關性進一步揭示其作用機制，使其成為前列腺癌免疫治療的潛在靶點。

在該研究中， Ausbian進口胎牛血清用于封閉。欲了解或購買Ausbian特級胎牛血清可以聯系北京締一生物400-166-8600.